Appropriate treatment

PreclinicalSmall molecule

Appropriate treatment is one of 4 small molecule programs targeting Chronic Lung Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Lung DiseaseActive, not recruiting

Chronic Lung DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Chronic Lung Disease

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Approved

1 2

Pulmicort

SSalix

Approved

1 3

Recombinant Thyroid-Stimulating Hormone

UUniversity College, London

Phase 1

1 4

Appropriate treatment

KKing Chulalongkorn Memorial Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Lung Disease1 trial

Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome

Completed·KKing Chulalongkorn Memorial Hospital··NCT05354583·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Appropriate treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Appropriate treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Appropriate treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — King Chulalongkorn Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKing Chulalongkorn Memorial Hospital

Appropriate treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Lung Disease1 trial

References

Drug Info

Quick Facts

Related News